Chronic cannabinoid receptor stimulation selectively prevents motor impairments in a mouse model of Huntington's disease

Neuropharmacology

Volumn 89, Issue , 2015, Pages 368-374

  Pietropaolo, Susanna ^a,b   Bellocchio, Luigi ^c   Ruiz Calvo, Andrea ^c   Cabanas, Magali ^a,b   Du, Zhuowei ^a,b   Guzmán, Manuel ^c   Garret, Maurice ^a,b   Cho, Yoon H ^a,b  

^a UMR 5287   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Cannabinoid receptor; DARPP 32; Huntington's disease; RotaRod test; Social behavior

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; HUNTINGTIN; BENZOXAZINE DERIVATIVE; CANNABINOID; MORPHOLINE DERIVATIVE; NAPHTHALENE DERIVATIVE; SEROTONIN TRANSPORTER; SLC6A4 PROTEIN, MOUSE;

ACUTE DRUG ADMINISTRATION; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; BRAIN NERVE CELL; CELL LOSS; CHRONIC DRUG ADMINISTRATION; COGNITION; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; HUNTINGTON CHOREA; MALE; MOTOR DYSFUNCTION; MOUSE; NEUROPROTECTION; NONHUMAN; PHENOTYPE; SINGLE DRUG DOSE; SOCIAL INTERACTION; TRANSGENIC MOUSE; TREATMENT RESPONSE; AGE; ANIMAL; BODY WEIGHT; BRAIN; C57BL MOUSE; COMPLICATION; DEPTH PERCEPTION; DRUG ADMINISTRATION; DRUG EFFECTS; EXPLORATORY BEHAVIOR; GENETICS; MAZE TEST; METABOLISM; MOTOR ACTIVITY; MOVEMENT DISORDERS; PATHOLOGY; TRINUCLEOTIDE REPEAT;

AGE FACTORS; ANIMALS; BENZOXAZINES; BODY WEIGHT; BRAIN; CANNABINOIDS; DRUG ADMINISTRATION SCHEDULE; EXPLORATORY BEHAVIOR; FEMALE; HUNTINGTON DISEASE; MALE; MAZE LEARNING; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MORPHOLINES; MOTOR ACTIVITY; MOVEMENT DISORDERS; NAPHTHALENES; RECEPTORS, CANNABINOID; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SPACE PERCEPTION; TRINUCLEOTIDE REPEATS;

EID: 84909950432     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2014.07.021     Document Type: Article

References (49)

1. W. Adriani, and G. Laviola Windows of vulnerability to psychopathology and therapeutic strategy in the adolescent rodent model Behav. Pharmacol. 15 2004 341 352
2. M. Arrasate, S. Mitra, E.S. Schweitzer, M.R. Segal, and S. Finkbeiner Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death Nature 431 2004 805 810
3. D. Baker, and G. Pryce The endocannabinoid system and multiple sclerosis Curr. Pharm. Des. 14 2008 2326 2336
4. C. Blazquez, A. Chiarlone, O. Sagredo, T. Aguado, M.R. Pazos, E. Resel, J. Palazuelos, B. Julien, M. Salazar, C. Borner, C. Benito, C. Carrasco, M. Diez-Zaera, P. Paoletti, M. Diaz-Hernandez, C. Ruiz, M. Sendtner, J.J. Lucas, J.G. de Yebenes, G. Marsicano, K. Monory, B. Lutz, J. Romero, J. Alberch, S. Gines, J. Kraus, J. Fernandez-Ruiz, I. Galve-Roperh, and M. Guzman Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease Brain 134 2011 119 136
5. C.L. Benn, R. Luthi-Carter, A. Kuhn, G. Sadri-Vakili, K.L. Blankson, S.C. Dalai, D.R. Goldstein, T.L. Spires, J. Pritchard, J.M. Olson, A. van Dellen, A.J. Hannan, and J.H. Cha Environmental enrichment reduces neuronal intranuclear inclusion load but has no effect on messenger RNA expression in a mouse model of Huntington disease J. Neuropathol. Exp. Neurol. 69 2010 817 827
6. R.A. Bodner, T.F. Outeiro, S. Altmann, M.M. Maxwell, S.H. Cho, B.T. Hyman, P.J. McLean, A.B. Young, D.E. Housman, and A.G. Kazantsev Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases Proc. Natl. Acad. Sci. U. S. A. 103 2006 4246 4251
7. V.J. Bolivar, K. Manley, and A. Messer Early exploratory behavior abnormalities in R6/1 Huntington's disease transgenic mice Brain Res. 1005 2004 29 35
8. J. Bouchard, J. Truong, K. Bouchard, D. Dunkelberger, S. Desrayaud, S. Moussaoui, S.J. Tabrizi, N. Stella, and P.J. Muchowski Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington's disease J. Neurosci. 32 2012 18259 18268
9. J.J. Burston, J.L. Wiley, A.A. Craig, D.E. Selley, and L.J. Sim-Selley Regional enhancement of cannabinoid CB1 receptor desensitization in female adolescent rats following repeated Delta-tetrahydrocannabinol exposure Br. J. Pharmacol. 161 2010 103 112
10. V. Chiodi, M. Uchigashima, S. Beggiato, A. Ferrante, M. Armida, A. Martire, R.L. Potenza, L. Ferraro, S. Tanganelli, M. Watanabe, M.R. Domenici, and P. Popoli Unbalance of CB1 receptors expressed in GABAergic and glutamatergic neurons in a transgenic mouse model of Huntington's disease Neurobiol. Dis. 45 2011 983 991
11. J.J. Clifford, J. Drago, A.L. Natoli, J.Y. Wong, A. Kinsella, J.L. Waddington, and K.S. Vaddadi Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington's disease Neuroscience 109 2002 81 88
12. D. Craufurd, J.C. Thompson, and J.S. Snowden Behavioral changes in Huntington disease Neuropsychiatry Neuropsychol. Behav. Neurol. 14 2001 219 226
13. Z.R. Crook, and D. Housman Huntington's disease: can mice lead the way to treatment? Neuron 69 2011 423 435
14. M.J. Dowie, M.L. Howard, L.F. Nicholson, R.L. Faull, A.J. Hannan, and M. Glass Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington's disease transgenic mice Neuroscience 170 2010 324 336
15. M.J. Dowie, H.B. Bradshaw, M.L. Howard, L.F. Nicholson, R.L. Faull, A.J. Hannan, and M. Glass Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease Neuroscience 163 2009 456 465
16. K. Duff, J.S. Paulsen, L.J. Beglinger, D.R. Langbehn, and J.C. Stout Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study Biol. Psychiatry 62 2007 1341 1346
17. M. Glass, R.L. Faull, and M. Dragunow Loss of cannabinoid receptors in the substantia nigra in Huntington's disease Neuroscience 56 1993 523 527
18. M. Glass, M. Dragunow, and R.L. Faull The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease Neuroscience 97 2000 505 519
19. M. Glass, A. van Dellen, C. Blakemore, A.J. Hannan, and R.L. Faull Delayed onset of Huntington's disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors Neuroscience 123 1 2004 207 212
20. H.E. Grote, N.D. Bull, M.L. Howard, A. van Dellen, C. Blakemore, P.F. Bartlett, and A.J. Hannan Cognitive disorders and neurogenesis deficits in Huntington's disease mice are rescued by fluoxetine Eur. J. Neurosci. 22 2005 2081 2088
21. G.G. Gould, A. Seillier, G. Weiss, A. Giuffrida, T.F. Burke, J.G. Hensler, C. Rock, A. Tristan, L.R. McMahon, A. Salazar, J.C. O'Connor, N. Satsangi, R.K. Satsangi, T.T. Gu, K. Treat, C. Smolik, and S.T. Schultz Acetaminophen differentially enhances social behavior and cortical cannabinoid levels in inbred mice Prog. Neuropsychopharmacol. Biol. Psychiatry 38 2012 260 269
22. J. Haller, N. Bakos, M. Szirmay, C. Ledent, and T.F. Freund The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety Eur. J. Neurosci. 16 2002 1395 1398
23. M. Haring, N. Kaiser, K. Monory, and B. Lutz Circuit specific functions of cannabinoid CB1 receptor in the balance of investigatory drive and exploration PLoS One 6 2011 e26617
24. I. Katona, and T.F. Freund Endocannabinoid signaling as a synaptic circuit breaker in neurological disease Nat. Med. 14 2008 923 930
25. M. Klugmann, A. Goepfrich, C.M. Friemel, and M. Schneider Aav-mediated overexpression of the CB1 receptor in the mPFC of adult rats alters cognitive flexibility, social behavior, and emotional reactivity Front. Behav. Neurosci. 5 2011 37
26. Y. Litvin, A. Phan, M.N. Hill, D.W. Pfaff, and B.S. McEwen CB1 receptor signaling regulates social anxiety and memory Genes. Brain Behav. 12 2013 479 489
27. M. Maccarrone, N. Battista, and D. Centonze The endocannabinoid pathway in Huntington's disease: a comparison with other neurodegenerative diseases Prog. Neurobiol. 81 2007 349 379
28. K. Mackie Distribution of cannabinoid receptors in the central and peripheral nervous system Handb. Exp. Pharmacol. 2005 299 325
29. L. Mangiarini, K. Sathasivam, M. Seller, B. Cozens, A. Harper, C. Hetherington, M. Lawton, Y. Trottier, H. Lehrach, S.W. Davies, and G.P. Bates Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice Cell 87 1996 493 506
30. N.K. Mazarakis, A. Cybulska-Klosowicz, H. Grote, T. Pang, A. Van Dellen, M. Kossut, C. Blakemore, and A.J. Hannan Deficits in experience-dependent cortical plasticity and sensory-discrimination learning in presymptomatic Huntington's disease mice J. Neurosci. 25 2005 3059 3066
31. E.A. McCaw, H. Hu, G.T. Gomez, A.L. Hebb, M.E. Kelly, and E.M. Denovan-Wright Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice Eur. J. Biochem 271 2004 4909 4920
32. R. Mechoulam, and E. Shohami Endocannabinoids and traumatic brain injury Mol. Neurobiol. 36 2007 68 74
33. S. Mievis, D. Blum, and C. Ledent Worsening of Huntington disease phenotype in CB1 receptor knockout mice Neurobiol. Dis. 42 2011 524 529
34. J. Miller, M. Arrasate, B.A. Shaby, S. Mitra, E. Masliah, and S. Finkbeiner Quantitative relationships between huntingtin levels, polyglutamine length, inclusion body formation, and neuronal death provide novel insight into huntington's disease molecular pathogenesis J. Neurosci. 30 2010 10541 10550
35. B. Naver, C. Stub, M. Moller, K. Fenger, A.K. Hansen, L. Hasholt, and S.A. Sorensen Molecular and behavioral analysis of the R6/1 Huntington's disease transgenic mouse Neuroscience 122 2003 1049 1057
36. P.T. Nguyen, C.L. Schmid, K.M. Raehal, D.E. Selley, L.M. Bohn, and L.J. Sim-Selley beta-arrestin2 regulates cannabinoid CB1 receptor signaling and adaptation in a central nervous system region-dependent manner Biol. Psychiatry 71 2012 714 724
37. J. Palazuelos, T. Aguado, M.R. Pazos, B. Julien, C. Carrasco, E. Resel, O. Sagredo, C. Benito, J. Romero, I. Azcoitia, J. Fernandez-Ruiz, M. Guzman, and I. Galve-Roperh Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity Brain 132 2009 3152 3164
38. R.G. Pertwee Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities Philos. Trans. R. Soc. Lond. B Biol. Sci. 367 2012 3353 3363
39. S. Pietropaolo, A. Guilleminot, B. Martin, F.R. D'Amato, and W.E. Crusio Genetic-background modulation of core and variable autistic-like symptoms in FMR1 knock-out mice PLoS One 6 2011 e17073
40. S. Pietropaolo, P. Delage, S. Cayzac, W.E. Crusio, and Y.H. Cho Sex-dependent changes in social behaviors in motor pre-symptomatic R6/1 mice PLoS One 6 2011 e19965
41. S. Pietropaolo, P. Delage, F. Lebreton, W.E. Crusio, and Y.H. Cho Early development of social deficits in APP and APP-PS1 mice Neurobiol. Aging 33 2012 1002 e1017-1027
42. E.L. Scotter, C.E. Goodfellow, E.S. Graham, M. Dragunow, and M. Glass Neuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington's disease Br. J. Pharmacol. 160 2010 747 761
43. A. Seillier, A.A. Martinez, and A. Giuffrida Phencyclidine-induced social withdrawal results from deficient stimulation of cannabinoid CB(1) receptors: implications for schizophrenia Neuropsychopharmacology 38 2013 1816 1824
44. L.P. Spear The adolescent brain and age-related behavioral manifestations Neurosci. Biobehav Rev. 24 2000 417 463
45. T.L. Spires, H.E. Grote, N.K. Varshney, P.M. Cordery, A. van Dellen, C. Blakemore, and A.J. Hannan Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism J. Neurosci. 24 2004 2270 2276
46. S.J. Tabrizi, D.R. Langbehn, B.R. Leavitt, R.A. Roos, A. Durr, D. Craufurd, C. Kennard, S.L. Hicks, N.C. Fox, R.I. Scahill, B. Borowsky, A.J. Tobin, H.D. Rosas, H. Johnson, R. Reilmann, B. Landwehrmeyer, and J.C. Stout Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data Lancet Neurol. 8 2009 791 801
47. V. Trezza, and L.J. Vanderschuren Divergent effects of anandamide transporter inhibitors with different target selectivity on social play behavior in adolescent rats J. Pharmacol. Exp. Ther. 328 2009 343 350
48. V. Trezza, V. Cuomo, and L.J. Vanderschuren Cannabis and the developing brain: insights from behavior Eur. J. Pharmacol. 585 2008 441 452
49. A. van Dellen, C. Blakemore, R. Deacon, D. York, and A.J. Hannan Delaying the onset of Huntington's in mice Nature 404 2000 721 722